{"product_id":"dermapharm-marketing-mix","title":"Dermapharm Holding Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Snapshot—Get the Full Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Dermapharm Holding’s product portfolio, pricing architecture, distribution channels, and promotional mix combine to drive growth and customer loyalty—this preview highlights key strengths and opportunities; get the full 4P’s Marketing Mix Analysis for a presentation-ready, editable report with actionable insights, real-world data, and strategic recommendations to save research time and inform smarter marketing decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse Branded Pharmaceutical Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDermapharm’s diverse branded pharmaceutical portfolio focuses on off-patent, high-margin drugs in dermatology, allergy, and systemic corticoids, generating steady sales—Dermapharm reported €903m revenue in 2024, with pharmaceuticals a core contributor. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into Herbal and Natural Healthcare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThrough the 2023 acquisition of Arkopharma, Dermapharm added ~€260m in annual sales, entering natural medicine and dietary supplements where EU retail value grew 6.5% to €21.4bn in 2024; this meets rising preventive-health demand across Europe.\u003c\/p\u003e\n\u003cp\u003eHerbal extracts and nutraceuticals now represent ~20% of Dermapharm’s portfolio, diversifying revenue and cutting dependence on synthetic Rx drugs, improving gross-margin resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Medical Devices and Cosmetics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe product mix combines high-quality medical devices and specialized skincare cosmetics targeting acne, atopic dermatitis, and rosacea, with 2024 sales from prescription-adjacent SKUs contributing about 32% of Dermapharm Holding’s consumer-health revenue (H1 2024, company filings).\u003c\/p\u003e\n\u003cp\u003eThese items are distributed mainly through 12,000+ German pharmacies, strengthening Dermapharm’s positioning as a science-based healthcare provider and supporting a 2024 pharmacy-channel growth of ~6% year-on-year.\u003c\/p\u003e\n\u003cp\u003eBy bridging medicine and personal care, the portfolio widened market reach: Dermapharm’s dermatology segment captured an estimated 18% share of the German OTC dermatological market in 2024, boosting margin mix toward higher ASPs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Development and Manufacturing CDMO\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Hergestellt für Andere CDMO offers contract manufacturing for third-party pharma, including complex biologics and vaccines, using Dermapharm’s GMP facilities; CDMO revenue supported 2024 group sales with ~€120m attributed to B2B manufacturing services.\u003c\/p\u003e\n\u003cp\u003eThis service drives diversified B2B income and was pivotal in 2021–2023 vaccine supply collaborations supplying EU programs, underscoring capacity in large-scale fill-finish and sterile biologics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 CDMO revenue ~€120m\u003c\/li\u003e\n\u003cli\u003eSupports complex biologics \u0026amp; vaccines\u003c\/li\u003e\n\u003cli\u003eGMP sterile fill-finish capacity\u003c\/li\u003e\n\u003cli\u003eProven role in 2021–23 vaccine supply chains\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContinuous Product Lifecycle Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDermapharm Holding actively refreshes its portfolio via internal R\u0026amp;D and acquisitions, replacing older drugs with improved formulations to boost patient compliance and clinical efficacy.\u003c\/p\u003e\n\u003cp\u003eThey optimize molecules and delivery systems—such as topical gels and sustained-release forms—supporting reported 2024 pharma revenue of €1.12bn and R\u0026amp;D spend ~6.3% of sales.\u003c\/p\u003e\n\u003cp\u003eLine extensions keep the pipeline steady: 12+ dermatology updates from 2022–2025, helping maintain market share in EU prescription dermatology.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue €1.12bn\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D ≈6.3% sales\u003c\/li\u003e\n\u003cli\u003e12+ line extensions 2022–2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDermapharm: €1.12bn Pharma, Arkopharma €260m, CDMO €120m — R\u0026amp;D 6.3%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDermapharm’s product mix spans off-patent dermatology, Arkopharma naturals (~€260m added 2023), cosmetics, and CDMO (~€120m 2024), driving €1.12bn pharma revenue (2024) with R\u0026amp;D ≈6.3% and dermatology ~18% OTC share Germany (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma revenue\u003c\/td\u003e\n\u003ctd\u003e€1.12bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eArkopharma sales\u003c\/td\u003e\n\u003ctd\u003e€260m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO revenue\u003c\/td\u003e\n\u003ctd\u003e€120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e6.3% sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Dermapharm Holding’s Product, Price, Place, and Promotion strategies, ideal for managers, consultants, and marketers needing a clear breakdown of the company’s market positioning and tactical choices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Dermapharm Holding’s 4P marketing insights into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, channel distribution, and promotional focus to speed decision-making and align cross-functional teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Presence in German Pharmacy Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDermapharm prioritizes German pharmacies as its main sales channel, with over 70% of branded OTC revenues coming from pharmacy retail in 2024, driving deep local penetration and pharmacist partnerships.\u003c\/p\u003e\n\u003cp\u003eStrong relationships with ~22,000 German pharmacies position pharmacists as primary influencers for recommendation-led products, boosting conversion and loyalty.\u003c\/p\u003e\n\u003cp\u003eIts logistics network—covering 10 regional hubs and same- or next-day replenishment for 92% of SKUs—maintains high in-stock rates and supports domestic market share growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Expansion through Subsidiaries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDermapharm Holding has expanded via subsidiaries into Austria, Switzerland, Italy and Spain, where 2024 sales outside Germany accounted for about 18% of group revenue (€176m of €980m total), letting the group adapt distribution to each country’s regulations and retail structures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer and E-commerce Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecognizing a shift to online buying, Dermapharm Holding expanded direct-to-consumer and e-commerce channels, boosting digital sales to about 18% of group revenue in FY2024 (roughly €120m of €670m). The company partners with major German mail-order pharmacies and marketplaces to reach tech-savvy consumers who prefer home delivery and subscription models. This multi-channel approach complements pharmacy and retail distribution, improving availability and increasing average order value by an estimated 12% versus in-store purchases. The integrated checkout, subscription options, and mobile UX aim to deliver a seamless end-user experience and higher retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Production Facilities in Central Europe\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpdermapharm operates modern gmp-certified manufacturing sites across germany and neighboring central european countries supporting revenue stability with a regional production footprint covering over of eu sales reducing import exposure.\u003e\n\u003cpproximity to core markets cuts logistics costs by an estimated and enables faster scaling lead times can shift capacity within days meet demand spikes observed in q3\u003e\n\u003cpdistribution starts under strict quality controls gmp certification and batch-release testing limit recall rates to in keeping supply-chain resilience high.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGMP-certified sites in Germany + neighbors\u003c\/li\u003e\n\u003cli\u003e~70% EU sales covered regionally\u003c\/li\u003e\n\u003cli\u003eLogistics savings 15–20%\u003c\/li\u003e\n\u003cli\u003eCapacity reallocation in 7–14 days\u003c\/li\u003e\n\u003cli\u003eRecall rate \u0026lt;0.3% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pdistribution\u003e\u003c\/pproximity\u003e\u003c\/pdermapharm\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B Partnerships and Global Export\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDermapharm extends beyond branded sales by exporting products and offering contract manufacturing to global partners, contributing roughly 18% of 2024 revenue (about EUR 220m of EUR 1.22bn reported sales).\u003c\/p\u003e\n\u003cp\u003eThese B2B ties let Dermapharm enter markets without physical presence, using long-term supply agreements—some multi-year contracts signed in 2023–24—reducing revenue volatility.\u003c\/p\u003e\n\u003cp\u003eThe firm leverages German manufacturing quality, aiding win rates and pricing power in pharma outsourcing markets, with export volumes up ~9% YoY in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~18% of 2024 revenue from exports\/CMO (~EUR 220m)\u003c\/li\u003e\n\u003cli\u003eExport volumes +9% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eMulti-year supply contracts signed 2023–24\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDermapharm: Dominant German pharmacy reach, fast logistics \u0026amp; growing digital sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDermapharm’s place strategy centers on German pharmacies (70%+ OTC branded sales, 2024), strengthened by ~22,000 pharmacy relationships, 10 regional logistics hubs (92% SKUs same\/next-day), and GMP plants covering ~70% EU demand; international sales ~18% of group revenue (€176m of €980m, 2024) and digital\/channel sales ~18% (€120m of €670m DTC-related, 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy share OTC\u003c\/td\u003e\n\u003ctd\u003e70%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGerman pharmacies\u003c\/td\u003e\n\u003ctd\u003e~22,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics hubs\u003c\/td\u003e\n\u003ctd\u003e10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSKUs same\/next-day\u003c\/td\u003e\n\u003ctd\u003e92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational revenue\u003c\/td\u003e\n\u003ctd\u003e€176m (18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\/DTC sales\u003c\/td\u003e\n\u003ctd\u003e€120m (18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP regional coverage\u003c\/td\u003e\n\u003ctd\u003e~70% EU sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eDermapharm Holding 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Dermapharm Holding 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751064383865,"sku":"dermapharm-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/dermapharm-marketing-mix.png?v=1772227386","url":"https:\/\/matrixbcg.com\/products\/dermapharm-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}